Editado por: Silvia Pellitero-Rodrguez - University Hospital Germans Trias i Pujol Badalona Federico Vzquez Sanmiguel - University Hospital Germans Trias i Pujol Badalona ltima actualizacin : Octubre 2025 Los frmacos con accin sobre el receptor del pptido similar al glucagn tipo 1 (GLP-1) son efectivos en el tratamiento de enfermedades metablicas asociadas a la obesidad, como la apnea obstructiva del sueo (AOS), la enfermedad heptica metablica (EHMET) y la enfermedad renal crnica (ERC)
It raises heart rate in a dose-dependent way
Beyond testing, look at the ingredient list
resM, being a supplement with common botanical ingredients, is unlikely to cause significant side effects beyond mild digestive discomfort
Rare side effects include the development of gallstones (4.9% of patients), and pancreatitis (inflammation of the pancreas)
Yes, extensively in controlled trials using regulated pharmaceutical formulations